Global Health Updates: Profitability Promises and Drug Developments
The latest health updates include Centene's improved profitability forecast, US-initiated healthcare data-sharing plans involving major tech executives, the FDA's extended review of Bayer's menopause drug, EU's approval of Moderna's updated COVID-19 vaccine, and Sciwind Biosciences' talks on licensing a weight-loss drug in the US.
In recent health developments, Centene Corp revealed plans to achieve profitability across its three government-supported healthcare sectors by 2026. Despite marking a surprising quarterly loss and underachieving annual profit expectations, the insurer experienced a 5% rise in shares following the announcement.
In the United States, healthcare data-sharing innovations make headlines. This significant initiative, reported by Bloomberg, involves bringing esteemed tech executives to the White House. The event, led by Health and Human Services Secretary Robert F. Kennedy Jr. and Medicare Administrator Mehmet Oz, seeks to foster efficient healthcare data exchange.
The FDA's extension on Bayer's menopause drug review highlights ongoing regulatory processes. Additionally, Europe's drug regulator endorses Moderna's updated COVID-19 vaccine, while China's Sciwind Biosciences is negotiating U.S. licensing for its weight-loss medication.
(With inputs from agencies.)
- READ MORE ON:
- health
- Centene
- profitability
- Moderna
- COVID-19
- vaccine
- Sciwind
- weight-loss
- Bayer
- menopause
Google News